Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults-Reference-Cited by-同舟云学术

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Published:2019-01-16 Issue:3 Volume:15 Page:530-539
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Stacey Helen L.¹^ORCID,Rosen Jeffrey²,Peterson James T.³,Williams-Diaz Angela⁴,Gakhar Vanita⁴,Sterling Tina M.⁴,Acosta Camilo J.⁴,Nolan Katrina M.⁴^ORCID,Li Jianing⁴,Pedley Alison⁴,Benner Patrice⁴,Abeygunawardana Chitrananda⁴,Kosinski Michael⁴,Smith William J.⁴,Pujar Hari⁴,Musey Luwy K.⁴

Affiliation:

1. Diablo Clinical Research, Inc, Walnut Creek, CA, USA

2. Clinical Research of South Florida, Coral Gables, FL, USA

3. J. Lewis Research, Inc./Foothill Family Clinic, Salt Lake City, USA

4. Merck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USA

Funder

Merck

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link